Strongbridge Biopharma (Strongbridge Biopharma) Net-Net Working Capital : $0.22 (As of Jun. 2021)

View and export this data going back to 2013. Start your Free Trial

What is Strongbridge Biopharma Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Strongbridge Biopharma's Net-Net Working Capital for the quarter that ended in Jun. 2021 was $0.22.

The industry rank for Strongbridge Biopharma's Net-Net Working Capital or its related term are showing as below:

SBBP's Price-to-Net-Net-Working-Capital is not ranked
in the Biotechnology industry.
Industry Median: 4.02 vs SBBP: 9.09

Strongbridge Biopharma Net-Net Working Capital Historical Data

The historical data trend for Strongbridge Biopharma's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Strongbridge Biopharma Net-Net Working Capital Chart

Strongbridge Biopharma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Net-Net Working Capital

Get a 7-Day Free Trial

-0.11

-1.42

1.26

0.65

0.52

Strongbridge Biopharma Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Net-Net Working Capital	Get a 7-Day Free Trial															0.24	0.62	0.52	0.36	0.22

Competitive Comparison of Strongbridge Biopharma's Net-Net Working Capital

For the Biotechnology subindustry, Strongbridge Biopharma's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Strongbridge Biopharma's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Strongbridge Biopharma's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Strongbridge Biopharma's Price-to-Net-Net-Working-Capital falls into.

Strongbridge Biopharma Net-Net Working Capital Calculation

Strongbridge Biopharma's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2020 is calculated as

	Net-Net Working Capital		(A: Dec. 2020 )
=	(Cash, Cash Equivalents, Marketable Securities	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(87.522	+	0.75 * 2.801	+	0.5 * 1.103	-	55.495
-	0	-	0)	/	67.2438
=	0.52

Strongbridge Biopharma's Net-Net Working Capital (NNWC) per share for the quarter that ended in Jun. 2021 is calculated as

	Net-Net Working Capital		(Q: Jun. 2021 )
=	(Cash, Cash Equivalents, Marketable Securities	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(63.774	+	0.75 * 3.581	+	0.5 * 1.101	-	52.429
-	0	-	0)	/	67.7223
=	0.22

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.

Strongbridge Biopharma (NAS:SBBP) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.

Strongbridge Biopharma Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Strongbridge Biopharma's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Strongbridge Biopharma (Strongbridge Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Strongbridge Biopharma PLC (NAS:SBBP) » Definitions » Net-Net Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 Northbrook Drive, Suite 200, Trevose, PA, USA, 19053

Website

http://www.strongbridgebio.com

Strongbridge Biopharma PLC is a biopharmaceutical company which focuses on the development, in-licensing, acquisition, and commercialization of various complementary products and product candidates that target rare diseases. The product portfolio of the group includes COR-003(levoketoconazole) and COR-005 (veldoreotide). COR-003 is a cortisol inhibitor which is used for the treatment of endogenous cushing's syndrome and COR-005 a novel somatostatin analog, which is used for the treatment of acromegaly. In addition, it is also developing BP-2002 (gene modified probiotic) which will be used for the treatment of Diabetes. Geographically, business activity of the firm is primarily functioned through the United States.

Executives

David N Gill	director	C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Cdk Associates, L.l.c.	10 percent owner	C/O CAXTON CORPORATION, 731 ALEXANDER ROAD, BUILDING #2, PRINCETON NJ 08540
Bruce Kovner	10 percent owner	C/O CAXTON ASSOCIATES, 500 PARK AVENUE, NEW YORK NY 10022
Caxton Corp	10 percent owner	731 ALEXANDER ROAD, BUILDING 2, SUITE 500, PRINCETON NJ 08540
John Johnson	director, officer: Chief Executive Officer	DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Garheng Kong	director	712 COLLEGE AVENUE, MENLO PARK CA 94025
Jeffrey W Sherman	director	C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Marten Steen	director	60 LEVERONI COURT, NOVATO CA 94949
Hilde H Steineger	director	900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Stephen J Long	officer: Chief Legal Officer	C R BARD INC 730 CENTRAL AVENUE MURRAY HILL NJ 07974
Fredric J. Cohen	officer: Chief Medical Officer	900 NORTHBROOK DRIVE SUITE 200 TREVOSE PA 19053
Scott L. Wilhoit	officer: Chief Commercial Officer	900 NORTHBROOK DRIVE SUITE 200 TREVOSE PA 19053
Robert Matthew Lutz	officer: Chief Financial Officer	900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Richard S Kollender	officer: Chief Operating Officer	C/O QUAKER BIOVENTURES, CIRA CENTRE, 2929 ARCH STREET, 3RD FLOOR, PHILADELPHIA PA 19104-2868
A Brian Davis	officer: Chief Financial Officer	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380